JACCCapretti et al.Original Research

Alec Vahanian works in Structural Heart Disease affiliated with Université Paris Cité.
Alec Vahanian is an Emeritus Professor of Cardiology at Université Paris Cité in Paris, France. He served as Head of the Cardiology Department at Bichat Hospital from 1999 and previously at Tenon Hospital from 1994. He has authored guidelines for the European Society of Cardiology on valvular heart disease, heart failure, and atrial fibrillation.
895 pubs · 121,434 cites · h-index 126
MD
University Paris VI
1972
Emeritus Professor of Cardiology
Université Paris Cité
Head of Cardiology
Bichat Hospital · 1999 - Present
Head of Cardiology
Tenon Hospital · 1994 - 1999
Professor of Cardiology
University Paris VI · 1988 - Present
JACCCapretti et al.Original Research
JACCStone et al.Guideline
Adoption of standardized endpoints will improve consistency across transcatheter mitral valve trials; extends VARC methodology to mitral regurgitation.
EHJVahanianeditorial
There is a growing burden of infective endocarditis in the elderly, driven by increased life expectancy, with peak incidence occurring between 70 and 80 years of age.
EHJSambola et al.cohort
Confirms in a large prospective registry that vegetation size >10 mm alongside key clinical, microbiological, and haemodynamic factors independently predicts embolic events and 30-day mortality in left-sided infective endocarditis, supporting early surgical risk stratification.
JACCTaramasso et al.case-control
Transcatheter tricuspid valve intervention is associated with improved 1-year survival and reduced heart failure rehospitalization compared to medical therapy alone in patients with severe tricuspid regurgitation.
EHJKotecha et al.Original Research
The ESC has outlined a strategic roadmap to enhance and harmonize cardiovascular education and training across its member countries.
JACCUreña et al.Cohort Study
JACC. Cardiovascular imagingMessika–Zeitoun et al.cohort
This post hoc analysis of the MITRA-FR trial found no echocardiographic subset of patients with severe secondary mitral regurgitation, including those with disproportionate MR, that benefited from MitraClip implantation.
Interventional / Structural Cardiology · Abbott Northwestern Hospital
The outcomes have been really not much better than what we have with surgery.
Journal of the American College of CardiologyGuerrero et al.
Cardiologist, University of Muenster, Germany · University of Muenster
The choice of SAVR or TAVI is not simply based on a risk score or age. The heart team must weigh the risks and benefits of both procedures, particularly in the intermediate risk situation. Discussion should include age, comorbidities, anatomy, and outcomes of the centre for surgery and transcatheter intervention.
European Heart JournalSøndergaard et al.
JACCClavel et al.cohort
Severe aortic valve calcification measured by MDCT provides incremental prognostic value for survival in patients with aortic stenosis, independent of clinical and echocardiographic assessment.
EHJVahanianreview
Promising less-invasive option for suitable mitral stenosis anatomy; leaves open long-term comparative outcomes versus surgery in randomized trials.
JACCClavel et al.cross-sectional
May help resolve discordant AS grading; leaves open prospective validation before altering management.
EHJMessika‐Zeitoun et al.review
This review highlights significant gaps in the diagnosis and management of valvular heart disease, emphasizing the need for improved access to care and novel medical therapies to prevent disease progression.
Cardiologist, University of Ottawa Heart Institute · University of Ottawa Heart Institute
The low mortality observed in elderly patients similar to or lower than that of isolated aortic valve surgery is very encouraging, but should be tempered as slightly more stroke and pacemaker [implantation] were observed and only in-hospital outcome was available.
European Heart JournalNguyen et al.
JACCStone et al.Guideline
Supports consistent MR trial interpretation in practice; extends standardized endpoints across transcatheter device evaluations and regulatory review.
JACCLeon et al.Guideline
The Valve Academic Research Consortium (VARC) established standardized consensus definitions for clinical endpoints in TAVI trials to improve research quality and enable meaningful comparisons.
EHJAbdelhamid et al.cohort
Suboptimal adherence to Class I recommendations in severe rheumatic mitral valve disease identifies an implementation gap; leaves open whether increasing intervention rates improves outcomes.
NEJMAnker et al.Original Research
BackgroundWhether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation is uncertain.MethodsWe conducted a randomized, controlled trial involving patients with heart failure and moderate to severe functional mitral regurgitation from 30 sites in nine countries. The patients were assigned in a 1:1 ratio to either transcatheter mitral-valve repair and guideline-recommended medical therapy (device group) or medical therapy alone (control group). The three primary end points were the rate of the composite of first or recurrent hospitalization for heart failure or cardiovascular death during 24 months; the rate of first or recurrent hospitalization for heart failure during 24 months; and the change from baseline to 12 months in the score on the Kansas City Cardiomyopathy Questionnaire–Overall Summary (KCCQ-OS; scores range from 0 to 100, with higher scores indicating better health status).ResultsA total of 505 patients underwent randomization: 250 were assigned to the device group and 255 to the control group. At 24 months, the rate of first or recurrent hospitalization for heart failure or cardiovascular death was 37.0 events per 100 patient-years in the device group and 58.9 events per 100 patient-years in the control group (rate ratio, 0.64; 95% confidence interval [CI], 0.48 to 0.85; P=0.002). The rate of first or recurrent hospitalization for heart failure was 26.9 events per 100 patient-years in the device group and 46.6 events per 100 patient-years in the control group (rate ratio, 0.59; 95% CI, 0.42 to 0.82; P=0.002). The KCCQ-OS score increased by a mean (±SD) of 21.6±26.9 points in the device group and 8.0±24.5 points in the control group (mean difference, 10.9 points; 95% CI, 6.8 to 15.0; P<0.001). Device-specific safety events occurred in 4 patients (1.6%).ConclusionsAmong patients with heart failure with moderate to severe functional mitral regurgitation who received medical therapy, the addition of transcatheter mitral-valve repair led to a lower rate of first or recurrent hospitalization for heart failure or cardiovascular death and a lower rate of first or recurrent hospitalization for heart failure at 24 months and better health status at 12 months than medical therapy alone. (Funded by Abbott Laboratories; RESHAPE-HF2 ClinicalTrials.gov number, NCT02444338.)
JACCPonikowski et al.Original Research
Urges caution with M-TEER in functional MR and HF; leaves open refined patient selection for future trials.